orbitazine (SM-1) / Shenzhen Zhenxing Pharmaceutical Technology - LARVOL DELTA

SM-1 (procaspase-3 agonist) combined with temozolomide for recurrent high-grade glioma: First-in-class trial (ESMO 2025) - P=N/A | "Steady-state parameters (Cmin,ss, Cmax,ss, Cav,ss, AUC0-t,ss, AUC0-∞,ss) exhibited dose-proportional increases. Conclusions SM-1 shows favorable safety and tolerability in rHGGs patients, demonstrating synergistic efficacy with TMZ alongside promising antitumor activity and survival benefits."

Late-breaking abstract • Brain Cancer • Glioma • High Grade Glioma • Oncology • CASP3 • MGMT